Loading
A phase 2 trial of Lutetium-177 dotatate in pheochromocytoma and paraganglioma, run by Advanced Accelerator Applications, active and no longer recruiting.
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs is a phase 2 interventional study registered as NCT04711135 by Advanced Accelerator Applications, with 11 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2024-03-12. Interventions recorded: Lutetium [177Lu] oxodotreotide/dotatate. Conditions listed: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
11 enrolled.
SD 0.013; Figures from the ClinicalTrials.gov results section (first posted 2024-11-27), not from a publication · SD 0.0073
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Absorbed Radiation Doses in Target Organ, Total Bodyprimary | GEP-NET | 4 | 0.04 gy/gbq | - | - | link |
| PPGL | 6 | 0.041 gy/gbq |
Shares Lutetium-177 dotatate, Radioligand therapy (beta emitters), Novartis.
Shares Lutetium-177 dotatate, Novartis.
Shares Lutetium-177 dotatate, Radioligand therapy (beta emitters).
Shares Lutetium-177 dotatate, Radioligand therapy (beta emitters).
Shares Lutetium-177 dotatate, Radioligand therapy (beta emitters).
Shares Lutetium-177 dotatate, Radioligand therapy (beta emitters).